Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
IPO Year: 2021
Exchange: NASDAQ
Website: bioventus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $7.00 | Hold → Buy | Canaccord Genuity |
| 8/9/2023 | $4.00 → $6.00 | Hold → Buy | Craig Hallum |
| 11/22/2022 | Buy → Hold | Craig Hallum | |
| 11/9/2022 | $18.00 → $6.00 | Buy → Hold | Canaccord Genuity |
| 11/9/2022 | Overweight → Underweight | JP Morgan | |
| 3/15/2022 | $30.00 | Buy | Craig Hallum |
| 3/11/2022 | $20.00 → $18.00 | Overweight | Morgan Stanley |
| 11/15/2021 | $20.00 | Overweight | Morgan Stanley |
| 11/10/2021 | $25.00 | Overweight | JP Morgan |
| 7/1/2021 | $20.00 → $19.00 | Buy → Neutral | Goldman Sachs |
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiary, Bioness, to Accelmed Partners ("Accelmed"), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction includes a total cash consideration of $45 million, including $25 million in cash at close (subject to a working capital adjustment) and up to $20 million in potential post-closing earn-out payments. At the time of closing, the Company expects to net approximatel
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website
DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 12, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the "Amendment") to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, July 11, 2022 and March 31, 2023 (the "Credit Agreement"). Among other items, the Amendment provides for additional financial covenant relief through the Third Quarter of 2025, includin
DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company. The awards consist of 375,000 restricted share units and options to purchase 850,000 shares of the Company's Class A common stock. Both awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to Mr. Claypoole's continued employment with th
DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments o
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Bioventus Inc. (0001665988) (Issuer)
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website
DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 12, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
DURHAM, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday, November 7, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715-9871 or 1-646-307-1963 and refer to the Bioventus Inc. Conference Call or Conference ID 4502901. A live webcast of the call and accompanying materials will also be provided on the "Inves
DURHAM, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday, August 8, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715-9871 or 1-646-307-1963 and refer to the Bioventus Inc. Conference Call or Conference ID 8443075. A live webcast of the call and accompanying materials will also be provided on the "Invest
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company's management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update. At this time, the Company expects to report revenue for the quarter ended April 1, 2023, of approximately $119 million and Adjusted EBITDA of approximately $17 million. The Company expects to be in compliance with all of its financial covenan
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period ended April 1, 2023, on May 11, 2023. Due to complexity of its tax structure and the associated impact on the calculation of noncontrolling equity interest in the equity section of the Company's balance sheet, additional time is required to complete the calculation and file the Company's financial results. The resulting noncontrolling equity calculations should have no impact on the Company's reven
DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Invest
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus, Inc. C
SCHEDULE 13G/A - Bioventus Inc. (0001665988) (Subject)
10-Q - Bioventus Inc. (0001665988) (Filer)
8-K - Bioventus Inc. (0001665988) (Filer)
EFFECT - Bioventus Inc. (0001665988) (Filer)
424B3 - Bioventus Inc. (0001665988) (Filer)
S-3 - Bioventus Inc. (0001665988) (Filer)
8-K - Bioventus Inc. (0001665988) (Filer)
10-Q - Bioventus Inc. (0001665988) (Filer)
8-K - Bioventus Inc. (0001665988) (Filer)
8-K - Bioventus Inc. (0001665988) (Filer)
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex
DURHAM, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Mary Kay Ladone to the Company's Board of Directors, effective July 15, 2021. In addition, she was appointed to the Board's Audit and Risk Committee (the "Audit Committee") and Compensation Committee. Ladone, an accomplished executive serving large global health care companies over her more than 30-year career, will join the Board as an independent director. "We are very pleased to welcome Mary Kay to our Board as she will provide valuable experience and insights as we execute our strategy of growth
Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00
Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously
Craig Hallum downgraded Bioventus from Buy to Hold
Canaccord Genuity downgraded Bioventus from Buy to Hold and set a new price target of $6.00 from $18.00 previously
JP Morgan downgraded Bioventus from Overweight to Underweight
Craig Hallum initiated coverage of Bioventus with a rating of Buy and set a new price target of $30.00
Morgan Stanley reiterated coverage of Bioventus with a rating of Overweight and set a new price target of $18.00 from $20.00 previously
Morgan Stanley resumed coverage of Bioventus with a rating of Overweight and set a new price target of $20.00
JP Morgan resumed coverage of Bioventus with a rating of Overweight and set a new price target of $25.00
Goldman Sachs downgraded Bioventus from Buy to Neutral and set a new price target of $19.00 from $20.00 previously
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13D/A - Bioventus Inc. (0001665988) (Subject)
SC 13D/A - Bioventus Inc. (0001665988) (Subject)
SC 13G - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13D/A - Bioventus Inc. (0001665988) (Subject)
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. The company posted revenue of $1.058 billion, versus estimates of $974.361 million. Its earnings came in at 67 cents per share, versus expectations of 55 cents per share, according to data from Benzinga Pro. AppLovin shares jumped 14.8% to $85.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 60.3% to $2.71 in pre-market trading. Pop Culture reported revenue of $24 million for the six months ended Dec. 31, 2023, up from $12
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results. Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, according to Benzinga Pro. The company reported a quarterly loss of 60 cents per share, which missed analyst estimates for a loss of 48 cents per share. Exact Sciences shares dipped 17.4% to $49.15 in pre-market trading. Here are some big stocks recording losses in today's pre-mark
Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 to $8.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0.01% to 38,857.00 while the NASDAQ fell 0.20% to 16,316.79. The S&P 500 also rose, gaining, 0.03% to 5,182.40. Check This Out: Top 3 Energy Stocks That Are Ticking Portfolio Bombs Leading and Lagging SectorsMaterials shares rose by 1% on Tuesday. In trading on Tuesday, consumer discretionary shares fell by 0.8%. Top Headline Shares of Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) jumped around 24% on Tuesday following better-than-expected first-quarter financial results. Great Lakes Dredge & Dock posted quarterly earnings of 31 cents per
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday’s session following weaker-than-expected quarterly results. Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of 87 cents per share. The company’s sales came in at $382.281 million versus estimates of $389.264 million, according to data from Benzinga Pro. Beyond shares dipped 20.8% to $17.34 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Golden Sun Health Technology Group Limited (NASDAQ:GSUN) shares gained 94.7% to $5.60. Golden Sun Health Technology Group regained compliance with Nasdaq continued listing requirement. MMTec, Inc. (NASDAQ:MTC) gained
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today. Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million. Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million. Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market valu
2024 Financial Guidance: Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects: Net sales of $535 million to $550 million—An increase of $15 million from previous guidance Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.07) by 200 percent. This is a 126.92 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $129.457 million which beat the analyst consensus estimate of $118.380 million by 9.36 percent. This is a 8.73 percent increase over sales of $119.059 million the same period last year.
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ:BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results. Blend Labs posted quarterly loss of 9 cents per share, in-line with market estimates of 9 cents per share. The company’s quarterly sales came in at $36.10 million versus estimates of $36.93 million, according to data from Benzinga Pro. Blend Labs shares jumped 24.3% to $2.92 on Friday. Here are some other big stocks recording gains in today’s session. Cardlytics, Inc. (NASDAQ:CDLX) jumped 57.1% to $12.86 after the company reported better-than-expected fourth-quar